At the end of every year, each field selects the ‘Top 10 News of the Year’ or ‘Things to Pay Attention to next year.’ The same goes for the scientific community.
‘Nature Medicine’, an international academic journal in the field of medicine, published a special analysis report titled ‘11 clinical trials to watch in 2024’ on December 8. Advances in artificial intelligence (AI) technology are expected to open up various possibilities in the medical field, but their use in actual patient treatment is still extremely limited. Nature analyzed that clinical trials related to the application of AI to the medical field will attract particular attention next year.
The ‘MARS-ED clinical trial’ conducted at Maastricht University Hospital in the Netherlands is evaluating an AI model that predicts the risk of death within one month for patients treated in the emergency room. Six hospitals in the UK are conducting a clinical trial targeting 150,000 patients to see whether AI can identify people who need additional computed tomography (CT) for early diagnosis of lung cancer using only chest X-rays. If this technology is actually applied, it is expected that it will be possible to reduce the cost burden on patients by identifying in advance whether patients require expensive imaging diagnosis.
A series of notable clinical trials related to cancer treatment are also being conducted. Erasmus University Hospital in the Netherlands is also conducting a clinical trial comparing about 26,000 people to determine whether it is more effective to perform lung cancer screening every year or every other year to lower lung cancer mortality. In addition, global pharmaceutical company AstraZeneca is conducting clinical trials on the efficacy and safety of an anticancer drug called ‘Trastuzumab deruxtecan’ for breast cancer patients with the HER2 protein, which promotes cancer cell growth. HER2-positive breast cancer is known to be a cancer with a very high risk of recurrence.
A clinical trial led by the Netherlands Cancer Institute will be conducted next year to compare the efficacy of adjuvant treatments that can be used in combination with immunotherapy drugs to treat melanoma, a skin cancer. The research team is comparing the effects of cancer treatment and recurrence inhibition when using ‘nivolumab’ alone and when using ‘ipilimumab’ and ‘nivolumab’ in combination.
ì •ì‹ ê±´ê°• ë¶„ì•¼ì— ì„œë „ 2024ë…„ì— ì£¼ëª©í• ë§Œí•œ ìž„ìƒ ì‹œí—˜ì ´ 진 í–‰ë ì˜ˆì •ìž…ë‹ˆë‹¤. ìš°ì„ íŒŒí‚¤ìŠ¤íƒ„ì ˜ ì ¸ê°„ê°œë°œì—°êµ¬ìž¬ë‹¨(HDRF)ì € ì ˜ë£Œì§„ì ´ ë§Žì§ € ì•Šì € 지ì—ì— ê±°ì£¼í•˜ëŠ” 임산부가 ìš°ìš¸ì¦ ì „ ì•“ì „ ë•Œ ë „ì›€ì „ 줄 수 있는 ì• í”Œë¦¬ì¼€ì ´ì…˜(앱)ì „ 개발해 대면 ì§„ë £Œì™€ 효과를 ë¹„êµ í•˜ëŠ” ìž„ìƒ ì‹œí—˜ì „ ì§„í–‰í• ì˜ˆì •ìž…ë‹ˆë‹¤. ë˜ ì˜ êµ ê¸€ëž˜ìŠ¤ê³ ëŒ€í•™ì € ìœ„íƒ ë³´í˜¸ë¥¼ 받는 0~5세 ì•„ë ™ì „ 위 í•œ ì •ì‹ ê±´ê°• 개입 ëª¨ë ¸ì „ 개발해 기존 사회 복지 ì„œë¹„ìŠ¤ì ™€ 효과, 비용 íš¨ìœ¨ì„±ì „ ì¡°ì‚¬í• ì˜ˆì •ìž…ë‹ˆë‹¤.
ì ´ ë°–ì— ë „ ì ¸ê°„ ë°°ì•„ ì¤„ê¸°ì„¸í ¬ì— ì„œ ìœ ëž˜í•œ ë „íŒŒë¯¼ ì‹ ê²½ì „¸í ¬ë¥¼ ì¤’ì¦ íŒŒí‚¨ìŠ¨ë³’ì „ ì•“ê³ ìžˆëŠ” 50~75세 í™˜ìž ë‡Œì— ì ´ì‹ í•˜ëŠ” â €˜STEM-PD’ ìž„ìƒ ì‹œí—˜ë „ ëˆˆê¸¸ì „ ë •ë‹ˆë‹¤. ë˜ ê°€ì¡±ë ¥ì „ 가진 ìœ ì „ì ê³ ì½œë ˆìŠ¤í…Œë¡¤í˜ˆì¦ í™˜ìž ì ˜ ì½œë ˆìŠ¤í…Œë¡¤ì „ 낮춰 주기 위한 DNA 염기 íŽ¸ì§’ì— ê´€í•œ ì—°êµ¬ë „ ë‚´ë…„ì — 진행ë ê³„íš ìž…ë‹ˆë‹¤. 갖가지 우울한 뉴스들로 ê°€ë“ í•œ ìš”ì¦˜ì ´ì§€ë§Œ ê³¼í• ™ê³„는 ë‚´ë…„ì— ë „ ì ¸ë¥˜ì ˜ ê±´ê°•ê³¼ ë°œì „ì „ 위한 ë°œê±¸ì Œì „ ë© ˆì¶”지 ì•Šì „ 것으로 보입니다.
ì ì©í 기ì
2023-12-13 14:40:21
#step #overcoming #breast #cancer #Parkinsons #disease #Dream #extending #life.. #Pay #attention #clinical #trials #year유용하 #기자의 #사이언스 #톡
